Atibuclimab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Atibuclimab Usage And Synthesis

Uses

Atibuclimab, is a chimeric monoclonal antibody directed against CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab can be used for the research of amyotrophic lateral sclerosis[1]. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist[2].

References

[1] Henderson RD, Agosti JM, McCombe PA, et al. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis. Medicine (Baltimore). 2021;100(42):e27421. DOI:10.1097/MD.0000000000027421
[2] Verbon A, et al. IC14, an anti-CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory responses in humans. J Immunol. 2001;166(5):3599-3605. DOI:10.4049/jimmunol.166.5.3599

Atibuclimab(2417175-94-9)Related Product Information

• Robatumumab
• Ustekinumab
• Olaratumab
• Oportuzumab Monatox
• Otelixizumab
• Cetuximab
• Zalutumumab
• nimotuzumab
• Eptinezumab
• Afasevikumab